PD-L1 Stocks
Oncology-focused biotechnology firms in this cohort develop therapeutics targeting the Programmed Death-Ligand 1 pathway to inhibit immune evasion mechanisms in malignant tumors.
As of Oct 23, 2026, PD-L1 has 7 US-listed companies worth $13.8B combined. The median member moved +2.0% over the past week; NBP led at +8.7% and PHIO trailed at -2.1%.
Companies in PD-L1
- SMMT – Summit Therapeutics PLC, $12.3B
- ABUS – Arbutus Biopharma Corp, $648M
- CBIO – Crescent Biopharma, Inc., $532M
- NBP – NovaBridge Biosciences, $158M
- CHRS – Coherus BioSciences Inc, $156M
- PHIO – Phio Pharmaceuticals Corp, $10.9M
- TCON – TRACON Pharmaceuticals Inc, $109,725